Enanta Pharmaceuticals Inc
ENTA
Get informed when a big investor buys or sells
+ FollowMarket Cap$319M
Close$
$-7.91
161.1% downside
Current Fair Value
161.1% downsideOvervalued by 161.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $319.00 Million |
|---|---|
| Enterprise Value | $470.69 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.84 |
| Beta | 0.97 |
| Outstanding Shares | 21,380,000 |
Return
| Return on Equity | -53.17% |
|---|---|
| Return on Assets | -19.70% |
| Return on Invested Capital | -19.63% |
Valuation & Multiples
| P/E Ratio | -5.01 |
|---|---|
| PEG | 11.89 |
| Price to Sales | 4.32 |
| Price to Book Ratio | 2.59 |
| Enterprise Value to Revenue | 6.8 |
| Enterprise Value to EBIT | -8.94 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.4 |
| Debt to Equity | 1.6 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$-0.46
Average shareholder expectationRevenue Estimate
$17.03 M
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$-0.51
Average shareholder expectationRevenue Estimate
$16.76 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 38.12% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.08%▼ 125.14% |
|---|---|
| Total Invested | $243,221▼ 99.93% |
| Investors Holding | 9▼ 125.00% |
ESG Score
No data
About Enanta Pharmaceuticals Inc
CEO: Jay Luly